Australia says CSL unit Seqirus to discontinue Benpen injections from November
Australia says CSL unit Seqirus to discontinue Benpen injections from November May 27 (Reuters) - Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's CSL.AX unit Seqirus that it will be discontinuing all strengths of their Benpen injection products progressively due to commercial reasons.
CSL's vaccine arm notified the regulator that the discontinuation will start with the 600 milligrams (mg) strength from 30 November 2026.
(Reporting by Shivangi Lahiri in Bengaluru)
Recent news on CSL
See all newsAustralia's CSL faces investor proceeding over disclosure obligations (updated)
Australia's CSL faces investor proceeding over disclosure obligations
Citi says CSL's CEO pick brings key strengths
Australia's CSL names GSK executive Waterhouse as next CEO (updated)
Brief: CSL Limited Appoints Deborah Waterhouse As CEO And Managing Director